The global biopharma industry is moving beyond a model centered on simply expanding pipelines. Instead, development speed, capital efficiency, platform based strategies, and clinical execution capabilities are increasingly viewed as key competitive factors. This reflects a shift from focusing on how many assets a company owns to how effectively it designs its R&D portfolio and executes development programs. In practical discussions with global pharmaceutical companies and investors, questions are increasingly centered on portfolio structure and execution capabilities rather than on the number of individual assets. This suggests that R&D strategy is no longer seen as a research plan alone, but as a core narrative that explains a company’s long-term competitiveness. Global pharma and biotech companies are also rebalancing between early-stage innovation and later stage assets. On the early side, continued investment in innovative platforms and novel mechanisms is aimed at building long-term technological leadership. At the same time, later-stage assets with relatively lower clinical risk are being used to enhance near term visibility and revenue potential. This dual strategy reflects how global companies are managing short-term performance and long-term competitiveness parallelly. There is also growing recognition that platform-based approaches, centered on specific technologies or modalities, can provide more sustainable competitive advantages than single-asset strategies. In actual partner meetings, companies with platform structures often attract greater strategic interest due to their scalability and long-term collaboration potential. These trends offer important strategic implications for Korean companies as they rethink R&D strategy, pipeline construction, and global partnership approaches.

Click here to read the full article written by Georgina Kim published on pages 39-42 in the 2026 BIO KOREA International Convention conference preview.